Present and future of influenza prevention in pediatrics

Bibliography

• Mullooly JP, Barker WH. Impact of type A influenza on children: a retrospective study. Am J Public Health 1982;72:1008-16
   PubMed Web of Science ®Google Scholar
• Glezen WP, Decker M, Perrotta DM. Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978-1981. Am Rev Respir Dis 1987;136:550-5
   PubMed Web of Science ®Google Scholar
• Simonsen L, Fukuda K, Schonberger LB, The impact of influenza epidemics on hospitalizations. J Infect Dis 2000;181:831-7
   PubMed Web of Science ®Google Scholar
• Izurieta HS, Thompson WW, Kramarz P, Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000;342:232-9
   PubMed Web of Science ®Google Scholar
• Iwane MK, Edwards KM, Szilagyi PG, Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 2004;113:1758-64
   PubMed Web of Science ®Google Scholar
• Ampofo K, Gesteland PH, Bender J, Epidemiology, complications, and cost of hospitalization in children with laboratory-confirmed influenza infection. Pediatrics 2006;118:2409-17
   PubMed Web of Science ®Google Scholar
• Coffin SE, Zaoutis TE, Rosenquist AB, Incidence, complications, and risk factors for prolonged stay in children hospitalized with community-acquired influenza. Pediatrics 2007;119:740-8
   PubMed Web of Science ®Google Scholar
• Chiu SS, Chan K-H, Chen H, Virologically confirmed population-based burden of hospitalization caused by influenza A and B among children in Hong Kong. Clin Infect Dis 2009;49:1016-21
   PubMed Web of Science ®Google Scholar
• Principi N, Esposito S, Marchisio P, Socioeconomic impact of influenza on healthy children and their families. Pediatr Infect Dis J 2003;22(Suppl 10):S207-10
   PubMed Web of Science ®Google Scholar
• Bhat N, Wright JG, Broder KR, Influenza-associated deaths among children in the United States, 2003–2004. N Engl J Med 2005;353:2559-67
   PubMed Web of Science ®Google Scholar
• Louie JK, Schechter R, Honarmand S, Severe pediatric influenza in California, 2003–2005: implications for immunization recommendations. Pediatrics 2006;117:e610-18
   PubMed Web of Science ®Google Scholar
• Smith SM, Gums JG. Antivirals for influenza: strategies for use in pediatrics. Paediatr Drugs 2010;12:285-99
   Google Scholar
• Esposito S, Molteni CG, Daleno C, Clinical importance and impact on the households of oseltamivir-resistant seasonal A/H1N1 influenza virus in healthy children in Italy. Virol J 2010;7:202
   PubMedGoogle Scholar
• Esposito S, Molteni CG, Colombo C, Oseltamivir-induced resistant pandemic A/H1N1 influenza virus in a child with cystic fibrosis and Pseudomonas aeruginosa infection. J Clin Virol 2010;48:62-5
   PubMed Web of Science ®Google Scholar
• Shun-Shin M, Thompson M, Heneghan C, Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomized controlled trials. BMJ 2009;339:b3172
   PubMed Web of Science ®Google Scholar
• Edwards KM. The burden of influenza in children: time for prevention. Clin Infect Dis 2009;49:1022-4
   PubMed Web of Science ®Google Scholar
• Fiore AE, Uyeki TM, Broder K, Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010;59:1-62
   PubMedGoogle Scholar
• Esposito S, Principi N. The rational use of influenza vaccines in healthy children and children with underlying conditions. Curr Opin Infect Dis 2009;22:244-9
   PubMed Web of Science ®Google Scholar
• Heinonen S, Silvennoinen H, Lehtinen P, Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infect Dis 2011;11:23-9
   PubMed Web of Science ®Google Scholar
• Austria: Impfplan 2010 Osterreich: korrigiert. Available from: http://www.bmgfj.gv.at/cms/home/attachments/2/1/2/CH1015/CMS1287855495948/the_austrian_health_care_system_2010_e1.pdf
   Google Scholar
• Jefferson T, Rivetti A, Harnden A, Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008;2:CD004879
   PubMed Web of Science ®Google Scholar
• Mitchell DK, Ruben FL, Gravenstein S. Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003-2004. Pediatr Infect Dis J 2005;24:925-7
   PubMed Web of Science ®Google Scholar
• Ansaldi F, Canepa P, Parodi V, Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection. Vaccine 2009;27:3345-8
   PubMed Web of Science ®Google Scholar
• Zeman AM, Holmes TH, Stamatis S, Humoral and cellular immune response in children given annual immunization with trivalent inactivated influenza vaccine. Pediatr Infect Dis J 2007;26:107-15
   PubMed Web of Science ®Google Scholar
• Belshe RB, Edwards KM, Vesikari T, Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007;356:685-96
   PubMed Web of Science ®Google Scholar
• Oster G, Weycker D, Edelsberg J, Benefits and risks of live attenuated influenza vaccine in young children. Am J Manag Care 2010;16:e235-44
   PubMed Web of Science ®Google Scholar
• Marchisio P, Cavagna R, Maspes B, Efficacy of intranasal virosomal influenza vaccine in the prevention of recurrent acute otitis media in children. Clin Infect Dis 2002;35:168-74
   PubMed Web of Science ®Google Scholar
• Mutsch M, Zhou W, Rhodes P, Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004;350:896-903
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Smith HM, Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age. Pediatrics 2008;121:e568-73
   PubMed Web of Science ®Google Scholar
• Ashkenazi S, Vertruyen A, Aristegui J, Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006;25:870-9
   PubMed Web of Science ®Google Scholar
• Yang CF, Belshe RB, Kemble G, Genetic sequence analysis of influenza viruses and illness severity in ill children previously vaccinated with live attenuated or inactivated influenza vaccine. Vaccine 2010;28:5128-34
   PubMed Web of Science ®Google Scholar
• Nichol KL, Mendelman PM, Mallon KP, Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999;282:137-44
   PubMed Web of Science ®Google Scholar
• De Villiers PJ, Steele AD, Hiemstra LA, Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine 2009;28:228-34
   PubMed Web of Science ®Google Scholar
• Eick AA, Wang Z, Hughes H, Comparison of the trivalent live attenuated vs. inactivated influenza vaccines among U.S. military service members. Vaccine 2009;27:3568-75
   PubMed Web of Science ®Google Scholar
• Rhorer J, Ambrose CS, Dickinson S, Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. Vaccine 2009;27:1101-10
   PubMed Web of Science ®Google Scholar
• Izurieta HS, Haber P, Wise RP, Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA 2005;294:2720-5
   PubMed Web of Science ®Google Scholar
• Bis Kersten C, Hirschberg H. Antigen delivery system. Expert Rev Vaccines 2004;3:453-62
   PubMedGoogle Scholar
• Falsey AR. New emerging technologies and the intradermal route: the novel way to immunize against influenza. Vaccine 2010;28(Suppl 4):D24-32
   PubMedGoogle Scholar
• Pearton M, Kang SM, Song JM, Changes in human Langerhans cells following intradermal injection of influenza virus-like particle vaccines. PLoS One 2010;5:e12410
   PubMed Web of Science ®Google Scholar
• Saville M, Marsh G, Hoffenbach A. Improving seasonal and pandemic influenza vaccines. Influenza Other Respir Viruses 2008;2:229-35
   Web of Science ®Google Scholar
• Sullivan SP, Koutsonanos DG, Del Pilar Martin M, Dissolving polymer microneedle patches for influenza vaccination. Nat Med 2010;16:915-20
   PubMed Web of Science ®Google Scholar
• Kim YC, Quan FS, Yoo DG, Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis 2010;201:190-8
   PubMed Web of Science ®Google Scholar
• Vankerckhoven V, Van Damme P. Clinical studies assessing immunogenicity and safety of intradermally administered influenza vaccines. Expert Opin Drug Deliv 2010;7:1109-25
   PubMed Web of Science ®Google Scholar
• Sugimura T, Ito Y, Tananari Y, Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination. Vaccine 2008;26:2700-5
   PubMed Web of Science ®Google Scholar
• Chiu SS, Chan KH, Tu W, Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial. Vaccine 2009;27:4834-9
   PubMed Web of Science ®Google Scholar
• Cools HJM, Gussekloo J, Remmerswaal JEM, Benefits of increasing the dose of influenza vaccine in residents of long-term facilities: a randomized placebo-controlled trial. J Med Virol 2009;81:904-14
   Google Scholar
• Keitel WA, Atmar RL, Cate TR, Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Inter Med 2006;166:1121-7
   PubMed Web of Science ®Google Scholar
• Couch Rb, Winokur P, Brady R, Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007;25:7656-63
   PubMed Web of Science ®Google Scholar
• Palache AM, Beyer WEP, Sprenger MJW, Antibody response after influenza immunization with various vaccines doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers. Vaccine 1993;11:3-7
   PubMed Web of Science ®Google Scholar
• Palache AM, Beyer WEP, Osterhaus ADME. Influenza vaccine dosages. Vaccine 2008;26:2305-6
   PubMed Web of Science ®Google Scholar
• Esposito S, Marchisio P, Ansaldi F, A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months. Vaccine 2010;28:6137-44
   PubMed Web of Science ®Google Scholar
• Bresson JL, Perronne C, Launay O, Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006;367:1657-64
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Edwards KM, Dekker CL, Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008;197:667-75
   PubMed Web of Science ®Google Scholar
• Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004;82:488-96
   PubMed Web of Science ®Google Scholar
• Calcagnile S, Zuccotti GV. The virosomal adjuvanted influenza vaccine. Expert Opin Biol Ther 2010;10:191-200
   PubMed Web of Science ®Google Scholar
• Arkema A, Huckriede A, Schoen P, Induction of cytotoxic activity by fusion active peptide-containing virosome. Vaccine 2000;18:1327-33
   PubMed Web of Science ®Google Scholar
• Huckriede A, Bungener I, Stegman T, The virosome concept for influenza vaccines. Vaccine 2005;23:S33-6
   Google Scholar
• Salleras L, Dominguez A, Pumarola T, Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illness and its social and economic consequences in children aged 3-14 years: a prospective cohort study. Vaccine 2006;24:6638-42
   PubMed Web of Science ®Google Scholar
• Marchisio P, Esposito S, Bianchini S, Efficacy of injectable trivalent virosomal-adjuvanted inactivated influenza vaccine in preventing acute otitis media in children with recurrent complicated or noncomplicated acute otitis media. Pediatr Infect Dis J 2009;28:855-9
   PubMed Web of Science ®Google Scholar
• Esposito S, Marchisio P, Cavagna R, Effectiveness of influenza vaccination of children with recurrent respiratory tract infections in reducing respiratory-related morbidity within households. Vaccine 2003;21:3162-8
   PubMed Web of Science ®Google Scholar
• Zuccotti G, Amendola A, Vigano A, Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma. Vaccine 2007;25:6692-8
   PubMed Web of Science ®Google Scholar
• Zuccotti GV, Scaramuzza A, Riboni S, Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus. Vaccine 2009;27:5357-62
   PubMed Web of Science ®Google Scholar
• Tanzi E, Esposito S, Bojanin J, Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. J Med Virol 2006;78:440-59
   PubMed Web of Science ®Google Scholar
• Vigano A, Zuccotti GV, Pacei M, Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. J Acquir Immune Defic Syndr 2008;48:289-96
   PubMed Web of Science ®Google Scholar
• Kanra G, Marchisio P, Feiterna-Sperling C, Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J 2004;23:300-6
   PubMed Web of Science ®Google Scholar
• Kusteiner O, Moser C, Lazar H, Durrer P. InflexalV-the influenza vaccine with the lowest albumin content. Vaccine 2006;24:6632-65
   PubMed Web of Science ®Google Scholar
• Esposito S, Gasparini C, Martelli A, Safe administration of an inactivated virosomal adjuvanted influenza vaccine in asthmatic children with egg allergy. Vaccine 2008;26:4664-8
   PubMed Web of Science ®Google Scholar
• O'Hagan DT, Wack A, Podda A. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development? Clin Pharmacol Ther 2007;82:740-4
   PubMed Web of Science ®Google Scholar
• O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007;6:699-710
   PubMed Web of Science ®Google Scholar
• Durando P, Icardi G, Ansaldi F. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin Biol Ther 2010;10:639-51
   PubMed Web of Science ®Google Scholar
• Vesikari T, Pellegrini M, Karvonen A, Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009;28:563-571
   PubMed Web of Science ®Google Scholar
• Vesikari T, Groth N, Karvonen A, MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 2009;27:6291-5
   PubMed Web of Science ®Google Scholar
• Esposito S, Pugni L, Daleno C, Monovalent pandemic influenza A/H1N1 MF59-adjuvanted vaccine in pre- and full-term children aged 6-23 months. Pediatrics 2011; In press
   Google Scholar
• Vesikari T, Karvonen A, Tilman S, Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 2010;126:e762-70
   PubMed Web of Science ®Google Scholar
• Black S, Della Cioppa G, Malfroot A, Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. Vaccine 2010;28:7331-6
   PubMed Web of Science ®Google Scholar
• Lippi G, Targher G, Franchini M. Vaccination, squalene and anti-squalene antibodies. Facts or fiction? Eur J Intern Med 2010;21:70-3
   PubMed Web of Science ®Google Scholar
• Carmona A, Omenaca F, Tejedor JC, Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine 2010;28:5837-44
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Horacek T, Knuf M, Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009;27:6284-90
   PubMed Web of Science ®Google Scholar
• Roman F, Vaman T, Gerlach B, Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010;28:1740-5
   PubMed Web of Science ®Google Scholar
• Diez-Domingo J, Garces-Sanchez M, Baldo JM, Immunogenicity and safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a Phase II, randomized, open, controlled study. Pediatr Infect Dis J 2010;29:e35-46
   PubMed Web of Science ®Google Scholar
• Waddington CS, Walker WT, Oeser C, Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010;340:c2649
   PubMed Web of Science ®Google Scholar
• Stropkovska A, Janulikova J, Vareckova E. Trends in development of the influenza vaccine with broader cross-protection. Acta Virol 2010;54:7-19
   PubMed Web of Science ®Google Scholar
• Genzel Y, Reichl U. Continuous cell lines as a production system for influenza vaccines. Expert Rev Vaccines 2009;8:1681-92
   PubMed Web of Science ®Google Scholar
• Barrett PN, Portsmouth D, Ehrlich HJ. Developing cell culture-derived pandemic vaccines. Curr Opin Mol Ther 2010;12:21-30
   PubMedGoogle Scholar
• Hussain AI, Cordeiro M, Sevilla E, Liu J. Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells. Vaccine 2010;28:3848-55
   PubMed Web of Science ®Google Scholar
• Smith LR, Wloch MK, Ye M, Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 2010;28:2565-72
   PubMed Web of Science ®Google Scholar
• Tompkins SM, Zhao ZS, Lo CY, Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007;13:426-35
   PubMed Web of Science ®Google Scholar
• Prabhu N, Prabakaran M, Ho HT, Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J Virol 2009;83:2553-62
   PubMed Web of Science ®Google Scholar
• Zaman K, Roy E, Arifeen SE, Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008;359:1555-64
   PubMed Web of Science ®Google Scholar
• Pownall M. Pregnant women to be included in target group for flu vaccination. BMJ 2010;341:c5432
   PubMedGoogle Scholar